The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 2×
“One notable exception has been the successful use of antibodies targeting the tyrosine kinase receptor HER-2-neu (ERBB2), which is disproportionably overexpressed in ER( ) breast cancer (Slamon et al., 2001; Lal et al., 2005).”
BackgroundGene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
Open source clustering software
de Hoon, M. J. L., Imoto, S., Nolan, J., & Miyano, S. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth078 · Cited by 3,043
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Use of a cDNA microarray to analyse gene expression patterns in human cancer
(1996) · Nature Genetics · doi:10.1038/ng1296-457 · Cited by 1,951
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Predicting the clinical status of human breast cancer by using gene expression profiles
West, M., Blanchette, C., Dressman, H., Huang, E., Ishida, S., Spang, R., Zuzan, H., Olson, J. A., Marks, J. R., & Nevins, J. R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201162998 · Cited by 1,318
Production and Actions of Estrogens
Gruber, C. J., Tschugguel, W., Schneeberger, C., & Huber, J. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmra000471 · Cited by 1,062
Mouridsen, H., Gershanovich, M., Sun, Y., Pérez-Carrión, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H. P., Jänicke, F., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2596 · Cited by 1,015
Aromatase Inhibitors in Breast Cancer
Smith, I. E., & Dowsett, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023246 · Cited by 905
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P., Bonnefoi, H., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G., Bergh, J., Cameron, D., Goldstein, D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208561 · Cited by 785
Relevance of Breast Cancer Cell Lines as Models for Breast Tumours: An Update
Lacroix, M., & Leclercq, G. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000014042.54925.cc · Cited by 782
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577 · cited 2×
“RNA target was synthesized from cDNA by in vitro transcription, and labeled with biotinylated nucleotides (Enzo Biochem, Farmingdale, NY, USA) (Holzbeierlein et al., 2004).”
MethodSelf-citationNongenomic steroid action: controversies, questions, and answers
LÖSEL, R. M., FALKENSTEIN, E., FEURING, M., SCHULTZ, A., TILLMANN, H.-C., ROSSOL-HASEROTH, K., & WEHLING, M. (2003) · Physiological Reviews · doi:10.1152/physrev.00003.2003 · Cited by 561
The program of androgen-responsive genes in neoplastic prostate epithelium
Nelson, P. S., Clegg, N., Arnold, H., Ferguson, C., Bonham, M., White, J., Hood, L., & Lin, B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182376299 · Cited by 482
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
Osborne, C. K., Wakeling, A., & Nicholson, R. I. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601629 · Cited by 414
Laganière, J., Deblois, G., Lefebvre, C., Bataille, A. R., Robert, F., & Giguère, V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505575102 · Cited by 367
Minireview: Nuclear Receptor Coactivators--An Update
McKenna, N. J., & O’Malley, B. W. (2002) · Endocrinology · doi:10.1210/en.143.7.2461 · Cited by 356
Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344 · cited 1×
“ERBB2 has been shown to stabilize AR protein levels and optimize binding of AR to promoters of androgen-regulated genes in prostate cancer cells (Mellinghoff et al., 2004).”
BackgroundAndrogens induce divergent proliferative responses in human breast cancer cell lines
Birrell, S. N., Bentel, J. M., Hickey, T. E., Ricciardelli, C., Weger, M. A., Horsfall, D. J., & Tilley, W. D. (1995) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(95)00005-k · Cited by 245
Lal, P., Tan, L. K., & Chen, B. (2005) · American Journal of Clinical Pathology · doi:10.1309/ymj3-a83t-b39m-rut9 · Cited by 221
Self-citationShurbaji, M. S., Kalbfleisch, J. H., & Thurmond, T. S. (1996) · Human Pathology · doi:10.1016/s0046-8177(96)90218-x · Cited by 208
Agoff, S. N., Swanson, P. E., Linden, H., Hawes, S. E., & Lawton, T. J. (2003) · American Journal of Clinical Pathology · doi:10.1309/42f00d0djd0j5edt · Cited by 206
Koziczak, M., Holbro, T., & Hynes, N. E. (2004) · Oncogene · doi:10.1038/sj.onc.1207331 · Cited by 160
Isola, J. J. (1993) · The Journal of Pathology · doi:10.1002/path.1711700106 · Cited by 157
Hall, R. E., Birrell, S. N., Tilley, W. D., & Sutherland, R. L. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90424-3 · Cited by 131
Nagahata, T., Onda, M., Emi, M., Nagai, H., Tsumagari, K., Fujimoto, T., Hirano, A., Sato, T., Nishikawa, K., Akiyama, F., et al. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02206.x · Cited by 121
Modulating nuclear receptor function: may the phos be with you
Shao, D., & Lazar, M. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7421 · Cited by 120
Dhanasekaran, S. M., Dash, A., Yu, J., Maine, I. P., Laxman, B., Tomlins, S. A., Creighton, C. J., Menon, A., Rubin, M. A., & Chinnaiyan, A. M. (2004) · The FASEB Journal · doi:10.1096/fj.04-2415fje · Cited by 115
ERGDB: Estrogen Responsive Genes Database
Tang, S. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkh083 · Cited by 94
Greeve, M., Allan, R. K., Harvey, J. A., & Bentel, J. M. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0320793 · Cited by 92
Tyrosine kinase signalling in breast cancer: Fibroblast growth factors and their receptors
Dickson, C., Spencer‐Dene, B., Dillon, C., & Fantl, V. (2000) · Breast Cancer Research · doi:10.1186/bcr53 · Cited by 90
Nantermet, P. V., Masarachia, P. J., Gentile, M. A., Pennypacker, B. L., Xu, J. Y., Holder, D., Gerhold, D. L., Towler, D. A., Schmidt, A., Kimmel, D. B., et al. (2004) · Endocrinology · doi:10.1210/en.2004-1132 · Cited by 82
Buchanan, G., Birrell, S. N., Peters, A. A., Bianco‐Miotto, T., Ramsay, K., Cops, E. J., Yang, M., Harris, J. M., Simila, H. A., Moore, N. L. T., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3077 · Cited by 79
Hall, R., Aspinall, J., Horsfall, D., Birrell, S., Bentel, J. M., Sutherland, R. L., & Tilley, W. D. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.513 · Cited by 71
Koziczak, M., & Hynes, N. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404252200 · Cited by 69
Carsol, J.-L., Gingras, S., & Simard, J. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.7.0875 · Cited by 38
Steketee, K., der Made, A. C. J. Z.-V., van der Korput, H. A. G. M., Houtsmuller, A. B., & Trapman, J. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01478 · Cited by 30
Tobias, J. S. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh485 · Cited by 23
Wilson, C., & Dering, J. (2004) · Breast Cancer Research · doi:10.1186/bcr917 · Cited by 21
Cited by
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
Pioneer transcription factors: establishing competence for gene expression
Zaret, K. S., & Carroll, J. S. (2011) · Genes & Development · doi:10.1101/gad.176826.111 · Cited by 1,589
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Triple-Negative Breast Cancer: An Unmet Medical Need
Hudis, C. A., & Gianni, L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-01 · Cited by 780
Self-citation
Metadata
- Authors
- Doane, A. S., Danso, M., Lal, P., Donaton, M., Zhang, L., Hudis, C., & Gerald, W. L.
- Venue
- Oncogene
- Published
- 2006-02-20
- Volume
- 25
- Issue
- 28
- Pages
- 3994-4008
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2043152591
- Cited by
- 603
- References
- 46
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.